Interleukin-10 (IL-10) is an ideal candidate cytokine for AdCMVhIL-10 induced a prolongation of median survival suppressing the alloimmune response in transplantation.to more than 87 days, with two of five transduced grafts To determine whether genetic modulation of the hepatic showing more than 100 days of ongoing survival, when graft with IL-10 could prolong survival following orthotopic compared with 11 days for grafts transduced with a control liver transplantation, we constructed a replication-deficient adenovirus vector carrying the E. coli ␤-galactosidase adenovirus vector expressing human IL-10 (AdCMVhILgene (P = 0.0021) and 11 days for untreated grafts 10). Intraportal injection of this vector into a donor rat 24-(P = 0.0021). Pathological findings occurring in the 48 h before grafting resulted in efficient release of IL-10AdCMVhIL-10-transduced hepatic grafts revealed no eviinto the circulation of a recipient rat after transplantation.dence of progressive rejection reaction resulting in graft Moreover, levels of hIL-10 from the suprahepatic venafailure. These results demonstrate that hepatic grafts cava were significantly (1.48-fold) higher than those from modulated by IL-10 gene transfer make local and effective the infrahepatic vena cava (P = 0.013), indicating local ILimmunosuppression feasible in the transplantation setting. 10 production within the transduced hepatic graft.

The prolongation of survival of IL-10 cDNA transferred liver allografts might be due to inhibition of the early phase of alloimmune-response by over expression of IL-10, despite the expression of IL-2 and interferon-gamma.

Background: Giant ovarian tumors are now rarely encountered, because of the wide availability of medical care, and most cases are benign. Case: A rare case of a giant ovarian cystadenoma in a 41-year-old woman, with such severe abdominal distension that she could not walk, is reported. Her abdominal girth was 141 cm. The patient was 151 cm tall and weighed 92.6 kg. Computed tomography (CT) showed a large, multilocular, cystic tumor that occupied the whole abdomen. The preoperative diagnosis was malignant ovarian tumor or ovarian cystadenoma. Results: On laparotomy, gradual intraoperative drainage of the tumor was first performed over 2 hours, and then total hysterectomy with bilateral salpingo-oophorectomy was performed successfully. Pathologic findings confirmed that the tumor was a mucinous cystadenoma. Conclusions: There is a lack of evidence on how to manage such giant tumors in the perioperative period; however, in the present case, intraoperative drainage and tumor resection were safely performed without complications. ( J GYNECOL SURG 28:215)

In general, schwannoma is a benign and slow-glowing neoplasm that rarely occurs in the gastrointestinal tract as a submucosal tumor (SMT), with the most common site being the stomach. As gastric schwannoma (GS) is a rare tumor, there is limited data in the literature about its clinical features. The diagnosis of schwannoma can only be made by pathological examination with positive staining for S-100 protein. It is necessary to obtain an accurate diagnosis to introduce optimal treatment options preoperatively. However, a precise diagnosis of GS is difficult, even with modern imaging techniques. On the other hand, a complete resection with a negative surgical margin (R0) of GS is considered the best treatment, with an excellent prognosis. We present a case of a 66-year-old female patient who underwent laparoscopic-assisted wedge gastrectomy for gastric SMT, pathologically diagnosed as GS, with positive staining for S-100 protein and negative for c-kit and CD34. At 12-month follow-up after surgery, there was no recurrence or metastasis of GS. Our treatment is appropriate and effective in case of GS exceeding 50 mm.

In general, the cancer-bearing rate of patients on dialysis is considered to be higher than that of healthy individuals. There is no established chemotherapy regimen for patients on hemodialysis (HD), but some reports have described chemotherapy administration in such patients according to HD conditions, residual renal function, and the drug metabolic pathway. We present a case involving a 76-year-old female patient on HD who underwent chemotherapy for mediastinal lymph node recurrence of neuroendocrine carcinoma of the breast (NECB) using 5-fluorouracil, epirubicin, and cyclophosphamide (FEC 100) and docetaxel (DTX). The patient showed a complete response to the treatment and survived longer than expected. This is the first report demonstrating a complete response to chemotherapy for the recurrence of primary NECB with the patient having survived for a long time after treatment.